|
|
 |
|
| News Release |
|
|
Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. |
| 2004 Release |
|
| December 17, 2004 |
|
Eisai Recieves A Positive Opinion for Zonegran Marketing Authorization From European Committee For Medicinal Products for Human Use (CHMP)
|
|
| November 19, 2004 |
|
Notice Concerning Completion of the Acquisition of the Company's Own Shares through ToSTNeT-2
|
|
| November 18, 2004 |
|
Notice Concerning the Acquisition of the Company's Own Shares through ToSTNeT-2
|
|
| November 15, 2004 |
|
Eisai In-licenses Anti-hepatitis B Agent clevudine From Bukwang Pharm (South Korea)
|
|
| October 29, 2004 |
|
Eisai Reacquires Worldwide Rights for a Triazole-Type Anti-Fungal Agent
|
|
| October 29, 2004 |
|
Eisai Announces Establishment of its Pharmaceuticals Marketing Subsidiary in India
|
|
| October 28, 2004 |
|
Eisai Announces Establishment of its European Regional Headquarters (Holding Company) in the U.K.
|
|
| October 22, 2004 |
|
Eisai Receives Approvals for New Formulations of ARICEPT (donepezil hydrochloride), Orally Disintegrating Tablet and Liquid Formulation in the U.S.
|
|
| August 27, 2004 |
|
Notice Concerning the Revision of Eisai Co., Ltd. and Consolidated Subsidiaries Quarterly Financial Report for the Period Ended June 30, 2004
|
|
| August 5, 2004 |
|
Eisai Launches SAHNE WHITE , A Medicated Skin Cream that Provides Protection Against Spots and Produces Smooth Skin
|
|
| July 30, 2004 |
|
Eisai's German Pharmaceuticals Marketing Subsidiary Starts Promotion of AstraZeneca's ENTOCORT , a locally acting Glucocorticosteroid for Inflammatory Bowel Diseases
|
|
| July 30, 2004 |
|
Notice Concerning Acquisition of the Company's Own Shares
|
|
| July 8, 2004 |
|
Eisai Receives European Marketing Authorization for PARIET (rabeprazole sodium) for Zollinger-Ellison Syndrome
|
|
| July 1, 2004 |
|
Notice Concerning Stock Options (Stock Acquisition Rights) Including the Amount Paid In Upon the Exercise of Stock Options
|
|
| June 30, 2004 |
|
Eisai Launches the First Treatment in Japan for Apnea of Prematurity Low Concentration Aminophylline, APNISSION Injection 15mg
|
|
| June 28, 2004 |
|
Eisai's Statement to AD2000 Clinical Trial Led By the Collaborative Group of University of Birmingham
|
|
| June 28, 2004 |
|
Eisai Launches New Formulation of ARICEPT , Rapid Disintegration Tablet, in Japan
|
|
| June 24, 2004 |
|
Notice on Allotment of Stock Options (Stock Acquisition Rights)
|
|
| June 18, 2004 |
|
Sanko Junyaku Co., Ltd., Subsidiary of Eisai Co., Ltd., to Launch New DCP Diagnostic Test Kit for Hepatocellular Carcinoma (HCC), LUMIPULSE PIVKA-II EISAI
|
|
| May 31, 2004 |
|
Eisai Submits MAA for New Formulation of ARICEPT (donepezil hydrochloride), Liquid Formulation in the European Union
|
|
| May 12, 2004 | |
Eisai Launches SACLON & SACLON Tablets with Increased Ingredients for Restoration of Damaged Stomach Mucosa and Acid Neutralization
|
|
| May 11, 2004 | |
Notice on Providing Stock Options in the Form of New Stock Issuance
|
|
| May 11, 2004 | |
Notice Concerning the Spin off of the Machinery Division of Eisai Co., Ltd
|
|
| May 7, 2004 | |
Amendment of the Co-Development, Licensing and Supply Agreement for the Obesity Management Agent KES524
|
|
| April 23, 2004 | |
ARICEPT Application for Vascular Dementia is Withdrawn in the European Union
|
|
| April 21, 2004 | |
PARIET (rabeprazole sodium) Approved for On-Demand Therapy of Symptomatic GORD in the European Union
|
|
| April 19, 2004 | |
Eisai Launches MENTEC HERB for Irritation-Associated Fatigue and Headache
|
|
| April 2, 2004 | |
Eisai's German Pharmaceuticals Marketing Subsidiary and GlaxoSmithKline Sign a Promotion Agreement for IMUREK, an Immunosuppressant
|
|
| March 31, 2004 | |
Eisai acquires anti-epileptic drug Zonegran (zonisamide) from Elan in North America and Europe
|
|
| March 1, 2004 | |
Eisai Launches CHOCOLA BB DRINK II, A New Vitamin B2 Drink for Alleviation of Skin Roughness
|
|
| February 25, 2004 | |
Announcement on the Adoption of "Company with Committees System"
|
|
| February 25, 2004 | |
Integration and Reorganization of Eisai's Machinery Operations
|
|
| February 10, 2004 | |
E2000, Transdermal Muscle Relaxant Application Withdrawn in Japan
|
|
| February 9, 2004 | |
Eisai Announces In-Licensing Agreement with Novartis for Rufinamide, A New Antiepileptic Agent
|
|
| February 3, 2004 | |
Notice Concerning Completion of the Acquisition of the Company's Own Shares through ToSTNeT-2
|
|
| February 2, 2004 | |
Notice Concerning the Acquisition of the Company's Own Shares through ToSTNeT-2
|
|
| January 30, 2004 | |
Eisai Commences Another US Legal Action Over Aciphex ANDA Filing
|
|
| January 15, 2004 | |
Eisai Launches JUSTAT Family of Products, Athlete's Foot and Ringworm Treatments
|
|
| January 7, 2004 | |
Eisai Inc., a U.S. Subsidiary of Eisai Co., Ltd., Assumes All Distribution Responsibilities for ACIPHEX
|
|
| | | |
|
|
|
